je.st
news
Tools for the Design of Vaccines to Help Reduce Clinical Failure
2014-09-11 16:23:44| drugdiscoveryonline Home Page
If you are involved in the pharma industry, then you are interested in saving lives. In the area of preventative medicine, therapeutic vaccines have proven to have a tremendous impact on the ability to save millions of lives. Similar to pharmaceuticals, vaccine development can take over 10 years and less than 10 percent of candidates reach commercialization. Reducing the cost of failure and increasing the chances of clinical success for vaccines is beneficial to both the pharma industry and those being treated for or protected from disease. Dr. Noel Smith, Senior Group Leader, Lonza Biologics Lonza understands this need and how ensuring the design and development of efficacious vaccines is critical for worldwide health. To address this, Dr. Noel Smith, Senior Group Leader, and the Applied Protein Services team at Lonza launched the Epibase™ Platform of in silico and in vitro immunogenicity screening services to help increase the chances of success for anyone aiming to develop safe and potent vaccines. “Our tools help researchers in the discovery stage of vaccine design and development to optimize their molecules before they progress into manufacturing for clinical trials,” says Dr. Smith. “Early assessment and optimization of immune responses allows you to focus your R&D resources on a smaller number of vaccine candidates with the greatest chance of success.”
Tags: design
tools
reduce
failure
Category:Biotechnology and Pharmaceuticals